Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.
Amgen (AMGN) Q4 2024 Earnings Call Transcript
All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speakers' prepared remarks. In order to ensure that everyone has a chance to participate,
Pipeline Problems Mar Amgen’s Q4 Beat
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 and the discontinuation of other programs.
Amgen profit beats estimates, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.
Amgen Surpasses Q4 Earnings Forecasts
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Amgen Inc. Q4 Profit Decreases, But Beats Estimates
Amgen Inc. (AMGN) reported a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.
Amgen: Q4 Earnings Snapshot
The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of $5.03 per share. The world's largest biotech drugmaker posted revenue of $9.09 billion in the period, also beating Street forecasts.
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
Amgen (AMGN) reported $9.09 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.9%. EPS of $5.31 for the same period compares to $4.71 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $8.
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
Amgen price target raised to $275 from $256 at BofA
BofA raised the firm’s price target on Amgen (AMGN) to $275 from $256 and keeps an Underperform rating on the shares. Q4 results were slightly ...
Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug
Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...
FiercePharma1d
With recent launches and more to come, Amgen's biosimilar business is trending up
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
AMGN Earnings: Amgen Slips on Soft EPS Guidance
Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...
FierceBiotech1d
Amgen's early-stage obesity asset slapped with FDA hold
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...
Amgen Inc (AMGN) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions
Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...